GH Secretagogue
Tesamorelin
Tesamorelin (Trans-3-hexenoic acid-GRF 1-44)
Evidence tier: FDA-approved (Egrifta). Phase III human trial data for visceral fat reduction.
| Molecular weight | 5135.9 Da |
| Molecular formula | C221H366N72O67S |
| CAS number | 218949-48-5 |
| Half-life | ~26 minutes |
| Administration | subcutaneous |
| Research dose | 2 mg/day subcutaneous (FDA-approved dose for HIV-associated lipodystrophy) |
Amino Acid Sequence
GRF(1-44) with N-terminal trans-3-hexenoic acid modification
Primary Mechanism
GHRH receptor agonism — stimulates pulsatile GH release, IGF-1 elevation
Studied For
visceral fat reductionHIV-associated lipodystrophycognitive function (Alzheimer's — ongoing trials)body composition
Reconstitution
Supplied as lyophilised powder with diluent. Follow manufacturer instructions.
Storage
Lyophilised: refrigerate at 2–8°C (not frozen). Reconstituted: use immediately or within 24 hours refrigerated.
Notes
One of very few peptides with full FDA approval. Strong human efficacy data for visceral adiposity. Ongoing trials for cognitive benefits in mild cognitive impairment.
This page contains affiliate links. If you purchase through these links, I may earn a commission at no extra cost to you.
These products are sold for research purposes only and are not intended for human consumption.